A Novel Monoclonal Antibody Degrades the Thyrotropin Receptor Autoantibodies in Graves' Disease
Authors' conclusion
Targeting the FcRn markedly reduces the disease-specific TSH-R-Ab in patients with GD. The novel and rapid TSH-R-Ab bioassay improves diagnosis and management of patients with GD.
Study context
- Population
- Patients with thyroidal and extrathyroidal Graves' disease (GD)
- Comparison
- Anti-FcRn monoclonal antibody (mAb) vs placebo
- Primary endpoint
- TSH-R-Ab degradation (serial serum TSH-R-Ab levels by 3 binding and cell-based assays)
Methodological detailsplacebo-controlled
- Placebo-controlled
Primary result
As reported in the abstract
Serum TSH-R-Ab levels · 12-week therapy; changes already at week 7
Early and significant decrease in serum TSH-R-Ab with mAb, in all 3 assays
>60%
Further findings
Correlation between TSH-R-Ab assays
- Binding immunoassay vs luciferase bioassay, r (P <.001)
- .91
- Binding vs cyclic adenosine monophosphate (cAMP) bioassay, r (P <.001)
- 0.86
- Luciferase vs cAMP bioassay, r (P =.006)
- 0.71
- Samples of both study groups
Correlation with extrathyroidal clinical parameters
- Serological results correlated with the course of clinical activity score and proptosis
Original publication
A Novel Monoclonal Antibody Degrades the Thyrotropin Receptor Autoantibodies in Graves' Disease. Endocr Pract. Published 18 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →